EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 6-7 (Juin-Juillet 2004) Med Sci (Paris), 20 6-7 (2004) 685-690 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 6-7, Juin-Juillet 2004
Page(s) 685 - 690
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004206-7685
Published online 15 June 2004
  1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis : Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91 : 2488–96. [Google Scholar]
  2. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247 : 349–58. [Google Scholar]
  3. Lusis AJ. Atherosclerosis. Nature 2000; 407 : 233–41. [Google Scholar]
  4. Assmann G, Cullen P, Jossa F, et al. Coronary heart disease : Reducing the risk : The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc Biol 1999; 19 : 1819–24. [Google Scholar]
  5. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium : Triumphs, concerns, and opportunities. N Engl J Med 1997; 337 : 1360–9. [Google Scholar]
  6. Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 1992; 6 : 103–10. [Google Scholar]
  7. Ros E. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000; 151 : 357–79. [Google Scholar]
  8. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 : S101–9. [Google Scholar]
  9. Davignon J. Advances in drug treatment of dyslipidemia : Focus on atorvastatin. Can J Cardiol 1998; 14 (suppl B) : 28B–38. [Google Scholar]
  10. Farnier M, Davignon J. Current and future treatment of hyperlipidemia : The role of statins. Am J Cardiol 1998; 82 : 3J–10. [Google Scholar]
  11. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials : A meta-analysis. Arch Intern Med 1999; 159 : 1793–802. [Google Scholar]
  12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98 : 2088–93. [Google Scholar]
  13. van Heek M, Davis H. Pharmacology of ezetimibe. Eur Heart J 2002; 4 (suppl) : J5–8. [Google Scholar]
  14. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003; 107 : 3124–8. [Google Scholar]
  15. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002; 89 : 11A–7. [Google Scholar]
  16. Evans M, Roberts A, Rees A. The future direction of cholesterol-lowering therapy. Curr Opin Lipidol 2002; 13 : 663–9. [Google Scholar]
  17. Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr Atheroscler Rep 2002; 4 : 343–9. [Google Scholar]
  18. Brown WV. Therapies on the horizon for cholesterol reduction. Clin Cardiol 2001; 24 : III24–7. [Google Scholar]
  19. Thompson GR, Naoumova RP. New prospects for lipid-lowering drugs. Exp Opin Invest Drugs 1998; 7 : 715–27. [Google Scholar]
  20. Pharmaproject. Richmond, Surrey (UK) : PJB Publications, 2003. [Google Scholar]
  21. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000; 131 : 63–70. [Google Scholar]
  22. Chevy F, Illien F, Wolf C, Roux C. Limb malformations of rat fetuses exposed to a distal inhibitor of cholesterol biosynthesis. J Lipid Res 2002; 43 : 1192–200. [Google Scholar]
  23. Chang G, Ruggeri RB, Harwood HJ, Jr. Microsomal triglyceride transfer protein (MTP) inhibitors : Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr Opin Drug Discov Dev 2002; 5 : 562–70. [Google Scholar]
  24. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001; 431 : 127–31. [Google Scholar]
  25. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998; 137 : 77–85. [Google Scholar]
  26. Accad M, Smith SJ, Newland DL, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA : Cholesterol acyltransferase 1. J Clin Invest 2000; 105 : 711–9. [Google Scholar]
  27. Willner EL, Tow B, Buhman KK, et al. Deficiency of acyl CoA : Cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2003; 100 : 1262–7. [Google Scholar]
  28. Brewer HB Jr. The lipid-laden foam cell : An elusive target for therapeutic intervention. J Clin Invest 2000; 105 : 703–5. [Google Scholar]
  29. Ichihashi T, Izawa M, Miyata K, et al. Mechanism of hypocholesterolemic action of S-8921 in rats : S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther 1998; 284 : 43–50. [Google Scholar]
  30. Izzat NN, Deshazer ME, Loose-Mitchell DS. New molecular targets for cholesterol-lowering therapy. J Pharmacol Exp Ther 2000; 293 : 315–20. [Google Scholar]
  31. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97 : 2917–23. [Google Scholar]
  32. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406 : 203–7. [Google Scholar]
  33. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans : A randomized phase II dose-response study. Circulation 2002; 105 : 2159–65. [Google Scholar]
  34. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289 : 1524–9. [Google Scholar]
  35. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99 : 7604–9. [Google Scholar]
  36. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23 : 1169–77. [Google Scholar]
  37. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22 : 717–26. [Google Scholar]
  38. Klappacher GW, Glass CK. Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. Curr Opin Lipidol 2002; 13 : 305–12. [Google Scholar]
  39. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002; 12 : 2545–8. [Google Scholar]
  40. Mashima R, Witting PK, Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 2001; 12 : 411–8. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.